Efficacy and tolerability of pharmacotherapies for borderline personality disorder

CNS Drugs

Volumn 22, Issue 8, 2008, Pages 671-692

  Bellino, Silvio ^a   Paradiso, Erika ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Amitriptyline, therapeutic use; Antidepressants, therapeutic use; Antipsychotics, therapeutic use; Aripiprazole, therapeutic use; Borderline personality disorders, treatment; Carbamazepine, therapeutic use; Desipramine, therapeutic use

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLONAZEPAM; DESIPRAMINE; DIURETIC AGENT; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE;

AFFECT; AGITATION; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; ANGER; APLASTIC ANEMIA; ATAXIA; BEHAVIOR CONTROL; BLURRED VISION; BORDERLINE STATE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONVULSION; DELIRIUM; DEPRESSION; DIAPHORESIS; DIARRHEA; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; ECG ABNORMALITY; EXFOLIATIVE DERMATITIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HOSTILITY; HUMAN; HYPERANDROGENISM; HYPERPARATHYROIDISM; HYPERPYREXIA; HYPERREFLEXIA; HYPONATREMIA; HYPOTHYROIDISM; IMPULSIVENESS; ISCHEMIA; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER TOXICITY; MENTAL INSTABILITY; MYDRIASIS; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NYSTAGMUS; OVARY POLYCYSTIC DISEASE; PANCREAS DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; RASH; REVIEW; SEDATION; SELF CONCEPT; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYNCOPE; TACHYCARDIA; TACHYPNEA; THROMBOCYTOPENIA; TREMOR; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; DRUG EVALUATION; DRUG TOLERANCE; HUMANS; META-ANALYSIS AS TOPIC;

EID: 46749103237     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822080-00005     Document Type: Review

References (152)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
2. Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapy for borderline patients. New York: John Wiley & Sons, 1999
3. Livesley WJ. A practical approach to the treatment of patients with borderline personality disorder. Psychiatr Clin North Am 2000; 23: 211-32
4. American Psychiatric Association. Practice guidelines for the treatment of patients with borderline personality disorder. Washington, DC: American Psychiatric Association, 2001
5. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry 1991; 148: 1647-58
6. Siever LJ, Trestman R. The serotonin system and aggressive personality disorder. Int Clin Psychopharmacol 1993; 8: 33-9
7. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcipromine. Arch Gen Psychiatry 1988; 45: 111-9
8. Parsons B, Quitkin FM, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989; 25: 524-34
9. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50 (5): 377-85
10. Soloff PH, George A, Nathan S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989; 9: 238-46
11. Links P, Steiner M, Boiago I, et al. Lithium therapy for borderline patients: preliminary findings. J Personal Disord 1990; 4: 173-81
12. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behaviour in personality disordered subjects. Arch Gen Psychiatry 1997; 54: 1081-8
13. Markovitz P. Pharmacotherapy of impulsivity, aggression, and related disorders. In: Hollander E, Stein DJ, editors. Impulsivity and aggression. New York: John Wiley & Sons, 1995: 263-87
14. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15: 23-9
15. Rinne T, de Kloet ER, Wouters L, et al. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin- releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry 2002; 52: 1102-12
16. Cornelius JR, Soloff PH, George A, et al. Haloperidol vs phenelzine in continuation therapy of borderline disorder. Psychopharmacol Bull 1993; 29 (2): 333-7
17. Lavin MR, Mendelowitz A, Kronig MH. Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biol Psychiatry 1993; 34 (3): 146-51
18. Shader RI, DiMascio A. Psychotropic drug side effects. Baltimore (MD): Williams and Wilkins, 1970
19. Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43: 691-7
20. Brown GL, Ebert MH, Goyer PF, et al. Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Am J Psychiatry 1982; 139: 741-6
21. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry Suppl 1989; 155: 52-62
22. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989; 46: 587-99
23. Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000; 23: 11-25
24. Soloff PH, Meltzer CC, Becker C, et al. Impulsivity and prefrontal hipometabolism in borderline personality disorder. Psychiatry Res 2003; 123: 153-63
25. Frankle WG, Lombardo I, New AS, et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. Am J Psychiatry 2005; 162 (5): 915-23
26. Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 1998; 62: 195-214
27. Soloff PH. Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 2000; 23: 169-92
28. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 885-93
29. Coccaro EF, Astill JL, Herbert JL, et al. Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. J Clin Psychopharmacol 1990; 10: 373-5
30. Cornelius JR, Soloff PH, Perel JM, et al. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26: 151-4
31. Cornelius J, Soloff PH, Perel J, et al. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol 1991; 11: 116-20
32. Markovitz PJ, Calabrese JR, Charles SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148: 1064-7
33. Teicher MH, Glod CA, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-10
34. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55: 137-41
35. Silva H, Jerez S, Paredes A, et al. Fluoxetine in the treatment of borderline personality disorder. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25 (6): 391-5
36. Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004 Mar; 65 (3): 379-85
37. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65: 903-7
38. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd. ed., revised. Washington, DC: American Psychiatric Association, 1987
39. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58 (1): 19-36
40. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006; 60 (4): 482-91
41. Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996; 16: 32-47S
42. Keck Jr PE, McElroy SL, Richt N, et al. What makes a drug a primary mood stabilizer? Mol Psychiatry 2002; 7 Suppl. 1: S8-14
43. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63: 146-51
44. Grof P. Mood-stabilizers: the archeology of the concept [commentary]. Bipolar Disord 2003; 5: 453-5
45. Harris M, Chandran S, Chakraborty N, et al. Mood stabilizers: the archeology of the concept. Bipolar Disord 2003; 5: 446-52
46. Keck Jr PE, McElroy SL. Redefining mood stabilization. J Affect Disord 2003; 73: 163-9
47. Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol 2005; 20: 225-36
48. Mackinnon DF, Pies R. Affective instability as rapid cycling: theoretical and clinical implications for borderline personality and bipolar spectrum disorders. Bipolar Disord 2006; 8: 1-14
49. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143: 519-22
50. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62: 199-203
51. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162: 621-4
52. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63: 442-6
53. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19: 287-91
54. Zanarini MC, Frankenburg FR, Gunderson JG. Pharmacotherapy of borderline outpatients. Compr Psychiatry 1988; 29: 372-8
55. Gardner DL, Cowdry RW. Pharmacotherapy of borderline personality disorder: a review. Psychopharmacol Bull 1989; 25: 515-23
56. Goldberg SC. Prediction of change in borderline personality disorder. Psychopharmacol Bull 1989; 25: 550-5
57. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-28
58. Stein DJ. Drug treatment of the personality disorders. Br J Psychiatry 1992; 161: 167-84
59. Delva NJ, Hawken ER. Preventing lithium intoxication: guide for physicians. Can Fam Physician 2001; 47: 1595-600
60. Fagiolini A, Kupfer DJ, Scott J, et al. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. Epidemiol Psychiatr Soc 2006; 15 (2): 123-7
61. Van Gerven HA, Boer WH. Chronic renal function disorders during lithium use. Ned Tijdschr Geneeskd 2006; 150 (31): 1715-8
62. Tang SW. Using lithium [letter]. Hong Kong Med J 2006; 12 (4): 253
63. Ghaemi SN, Ko JY. Oxcarbazepine treatment of bipolar disorder: a review of the literature. Prim Psychiatry 2002; 9: 55-9
64. Denicoff KD, Meglathery SB, Post RM, et al. Efficacy of carbamazepine compared with other agents: a clinical practice survey. J Clin Psychiatry 1994; 55: 70-6
65. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52: 13-9
66. Mattes J. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry Clin Neurosci 1990; 2: 159-64
67. Kravitz HM, Fawcett J. Carbamazepine in the treatment of affective disorders. Med Sci Res 1987; 15: 1-8
68. Blumer D, Heibronn M, Himmelhoch J. Indications for carbamazepine in mental illness: atypical psychiatric disorder or temporal lobe syndrome? Compr Psychiatry 1988; 29: 108-22
69. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24 (1): 91-103
70. Zubcevic S, Gavranovic M, Katica V, et al. Efficacy and tolerability of carbamazepine as the initial drug used in the treatment of epilepsy. Med Arch 2002; 56 (3 Suppl. 1): 26-9
71. Emrich H. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol 1990; 5 Suppl. 1: 83-8
72. Hellewell JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord 2002; 72 Suppl. 1: S23-34
73. Hummel B, Walden J, Stampfer R, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 2002; 4: 412-7
74. Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in the treatment of affective and schizoaffective disorders. Fortschr Neurol Psychiatr 2003; 71: 255-64
75. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 2003; 64 Suppl. 8: 9-14
76. Ghaemi SN, Berv DA, Klugman J, et al. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry 2003; 64: 943-5
77. Perugi G, Toni C, Frare F, et al. An open case study in Italy of oxcarbazepine, an effective mood stabilizer, in patients with drug resistant/intolerant bipolar I disorders [poster]. XVI Congress of European College of Neuropsychopharmacology; 2003 Sep 20-24; Prague
78. Raja M, Azzoni A. Oxcarbazepine versus valproate in mood and schizoaffective disorders. Int J Neuropsychopharm 2003; 6: 409-14
79. Benedetti A, Lattanzi L, Pini S, et al. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004; 79: 273-7
80. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6: 57-75
81. Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. J Clin Psychiatry 2004; 65: 738-9
82. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004; 65 Suppl. 10: 28-35
83. Gentry JR, Hill C, Malcolm R. New anticonvulsants: a review of applications for the management of substance abuse disorders. Ann Clin Psychiatry 2002; 14: 233-45
84. Leweke FM, Gerth CW, Koethe D, et al. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry 2004; 161: 1130-1
85. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005; 66: 1111-5
86. Martinez W, Ingenito A, Blakeslee M, et al. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy Behav 2006; 9 (3): 448-56
87. McAuley JW, Biederman TS, Smith JC, et al. Newer therapies in the drug treatment of epilepsy. Ann Pharmacother 2002; 36 (1): 119-29
88. Pol P. Enhancement of GABAergic inhibition: a mechanism of action of benzodiazepines, phenobarbital, valproate and L-cycloserine in the cat spinal cord. Electroencephalogr Clin Neurophysiol 1982; 36 Suppl.: 188-98
89. Wilcox JA. Divalproex sodium in the treatment of aggressive behaviour. Ann Clin Psychiatry 1994; 6: 17-20
90. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995; 7: 33-7
91. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995; 56: 506-10
92. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59: 676-80
93. Landy SH, McGinnis J. Divalproex sodium: review of prophylactic migraine efficacy, safety and dosage, with recommendations. Tenn Med 1999; 92: 135-6
94. Walia KS, Khan EA, Ko DH, et al. Side effects of antiepileptics: a review. Pain Pract 2004; 4 (3): 194-203
95. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38: 119-30
96. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998; 51: 333-43
97. Green B. Lamotrigine in mood disorders. Curr Med Res Opin 2003; 19: 272-7
98. Preston GA, Marchant BK, Reimherr FW, et al. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord 2004; 79: 297-303
99. Faught E, Matsuo FU, Schachter S, et al. Long-term tolerability of lamotrigine: data from a 6-year continuation study. Epilepsy Behav 2004; 5 (1): 31-6
100. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271 (12): 918-24
101. Hirsch LJ, Weintraub D, Du Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63 (6): 1022-6
102. Teicher M, Glod C, Aaronson S, et al. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989; 25: 535-49
103. Kutcher S, Papatheodorou G, Reiter S, et al. The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. J Psychiatry Neurosci 1995; 20: 113-8
104. Leone N. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982; 43: 148-50
105. Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984; 141 (11): 1455-8
106. Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorder treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43: 680-6
107. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect Disord 1982; 4 (4): 291-8
108. Quieffin J, Brochet E, Gamerman G, et al. Ventricular arrhythmia following thioridazine poisoning. Ann Cardiol Angiol 1991; 40 (4): 199-201
109. Lingjaerde O. Electrocardiographic changes, disturbances of cardiac rhythm, and sudden deaths during treatment with phenothiazine drugs. Tidsskr Nor Laegeforen 1967; 87 (2): 90-4
110. Jarema M, Sartorius N. Treatment of bipolar disorders with second generation antipsychotic medications. Neuro Endocrinol Lett 2005; 26 Suppl. 1: 5-7
111. Malhi GS, Berk M, Bourin M, et al. Atypical mood stabilizers: a typical role for atypical antipsychotics. Acta Psychiatr Scand Suppl 2005; 111 (426): 29-38
112. Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry 2005; 39: 652-61
113. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005; 7 Suppl. 4: 21-33
114. Conus P, Berk M, McGorry PD. Pharmacological treatment in the early phase of bipolar disorders: what stage are we at? Aust N Z J Psychiatry 2006; 40: 199-207
115. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402-5
116. Benedetti F, Sforzini L, Colombo C, et al. Low dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59: 103-7
117. Chengappa KN, Ebeling T, Kang JS, et al. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999; 60: 477-84
118. Kouzam HR, Donnelly NJ. Remission of selfmutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 1997; 185: 348-9
119. Szighethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psychopharmacol 1997; 17: 326-7
120. Schulz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46: 1429-35
121. Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psych Clin Neurosci 2001; 55: 161-2
122. Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63: 241-4
123. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62: 849-54
124. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104-9
125. Soler J, Pascual JC, Barrachina J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162: 1221-4
126. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163 (5): 833-8
127. Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61: 111-61
128. Kufferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 1997; 133: 323-8
129. Brecher M, Rak IW, Melvin K, et al. The longterm effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287-91
130. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a prelim-inary finding of an antipsychotic effect with only transient high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553-9
131. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 2003; 4: 42-4
132. Adityanjee A, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002; 63 Suppl. 13: 32-8
133. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005; 66: 1298-303
134. Perrella C, Carrus D, Costa E, et al. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 31 (1): 158-63
135. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2006; 67 (7): 1042-6
136. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325-37
137. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90
138. Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Rev Neurother 2004; 4 Suppl. 2: 17-25
139. Centorrino F, Fogarty KV, Cimbolli P, et al. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract 2005; 11 (4): 241-7
140. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005; 6 (12): 2091-101
141. Simon JS, Nemeroff CB. Aripiprazole augmentation for the treatment of partially responding and non responding patients with major depressive disorder. J Clin Psychiatry 2005; 66: 1216-20
142. Patkar AA, Peindl K, Mago R, et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006; 8 (2): 82-7
143. Mobascher A, Mobascher J, Schlemper V, et al. Aripiprazole pharmacotherapy of borderline personality disorder. Pharmacopsychiatry 2006; 39 (3): 111-2
144. Nickel MK, Loew TH, Gil FP. Aripiprazole in the treatment of borderline patients: II. An 18-month follow-up. Psychopharmacology 2007; 191 (4): 1023-6
145. Lambertenghi Deliliers G. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica 2000; 85 (3): 233-7
146. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007; 13 (1): 13-24
147. Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 2007; 61 (1): 54-8
148. Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol 2005; 28: 163-8
149. Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 2005; 7: 307-25
150. Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Aripiprazole Study Group. Am J Psychiatry 2003; 160: 1651-8
151. Nosè M, Cipriani A, Biancosino B, et al. Efficacy of pharmaco-therapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2006; 21 (6): 345-53
152. Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 2006; (1): CD005653